ID
20813
Beskrivning
This study is a prospective, interventional, open-label, multi-center early access program for the use of Ra-223 Cl2 in HRPC/CRPC (Hormone refractory prostate cancer / Castrate resistant prostate cancer) patients diagnosed with bone metastasis and to collect additional short and long term safety data on the product. NCT01618370
Nyckelord
Versioner (1)
- 20/03/2017 20/03/2017 -
Uppladdad den
20 de março de 2017
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Radium-223 Dichloride (Alpharadin) DRKS00006460 NCT01618370 in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases (Study Medication)
Radium 223 Dichloride (Alpharadin) - Study Medication
- StudyEvent: ODM
Similar models
Radium 223 Dichloride (Alpharadin) - Study Medication
- StudyEvent: ODM
C1948053 (UMLS CUI [1,2])
C0599112 (UMLS CUI [1,2])
C0444686 (UMLS CUI [1,2])
C0034553 (UMLS CUI [1,2])
C0585032 (UMLS CUI [1,2])
C1706071 (UMLS CUI [1,2])
C0585032 (UMLS CUI [1,3])
C1706071 (UMLS CUI [1,2])
C0580203 (UMLS CUI [1,3])
C0580203 (UMLS CUI [1,2])
C0392360 (UMLS CUI [1,2])